Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2021 at "European journal of haematology"
DOI: 10.1111/ejh.13697
Abstract: BACKGROUND Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of… read more here.
Keywords: relapsed refractory; class; triple class; multiple myeloma ... See more keywords
Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134558
Abstract: BACKGROUND Aneuploidy, defined by abnormal copy number changes of chromosomes, contributes to genome instability in multiple myeloma and has potential prognostic impact. Previous research has explored transcriptional pathways affected by aneuploidy. We aim to evaluate… read more here.
Keywords: research; analysis; aneuploidy; research funding ... See more keywords
Novel Therapies for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: A Review of Clinical Trials
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142903
Abstract: Introduction: Multiple myeloma (MM) is a neoplastic proliferation of plasma cells. It is the second most common hematological malignancy in the US. Although it is associated with poor prognosis, newer therapies have improved outcomes in… read more here.
Keywords: trial; dex; rrmm; efficacy ... See more keywords
Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8001
Abstract: 8001Background: POM, a standard-of-care treatment (Tx) in RRMM, has demonstrated synergistic anti-myeloma activity with dexamethasone (DEX) and proteasome inhibitors (PIs). POM + DEX is indicated f... read more here.
Keywords: low dose; dose dexamethasone; bortezomib low; dexamethasone ... See more keywords
Carfilzomib and dexamethasone (Kd56) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Updated overall survival (OS), safety, and subgroup analysis of ENDEAVOR.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8032
Abstract: 8032Background: The phase 3 ENDEAVOR trial demonstrated significantly improved PFS and OS with Kd56 vs Vd in RRMM patients (pts; Dimopoulos Lancet Oncol 2016 and 2017). We report updated data after... read more here.
Keywords: endeavor; carfilzomib dexamethasone; dexamethasone kd56; dexamethasone ... See more keywords
First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.8006
Abstract: 8006 Background: IBER is a novel cereblon E3 ligase modulator (CELMoD) with enhanced tumoricidal and immunostimulatory activities. Preclinically, IBER overcomes immunomodulatory drug (IMiD) resistance and has synergy with daratumumab (DARA), bortezomib (BORT), and DEX. Methods:… read more here.
Keywords: dose; rrmm; combination; dex ... See more keywords
Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.8038
Abstract: 8038 Background: High-risk cytogenetic abnormalities confer poor outcomes in MM patients (pts). In POLLUX, D-Rd demonstrated significant clinical benefit, including prolonged progression-free survival (PFS) vs lenalidomide and dexamethasone (Rd), and tolerability in RRMM pts. We… read more here.
Keywords: high risk; rrmm; risk; cytogenetic risk ... See more keywords
Sudden cardiac arrest after daratumumab infusion
Sign Up to like & getrecommendations! Published in 2019 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.4103/ijmpo.ijmpo_28_18
Abstract: 301 Sir, Despite recent therapeutic advances, remission induction after myeloma relapse remains a major clinical challenge. Treatment of relapsed refractory multiple myeloma (RRMM) in the background of resistance to immunomodulators and bortezomib usually results in… read more here.
Keywords: myeloma; sudden cardiac; cardiac arrest; arrest daratumumab ... See more keywords